Opinion

Video

ASCO 2024: Impact of RELATIVITY-047 on Metastatic Melanoma Management

Results from the RELATIVITY-047 study on the melanoma landscape are evaluated by Dr Evan Lipson.

Video content above is prompted by the following:

  • Discuss the data presented at ASCO 2024 on the RELATIVITY-047 study of nivolumab plus relatlimab vs nivolumab in patients with previously untreated metastatic or unresectable melanoma.
    • What was the objective of this study?
    • How was this study designed/what methodology was used?
    • What results were presented?
  • Please provide your key takeaways from this study.
    • How might these findings impact the management of patients with metastatic melanoma?
  • The study examined melanoma-specific survival (MSS) outcomes. What is the significance of sustained improvement in MSS observed with nivolumab plus relatlimab?
Related Videos
5 KOLs are featured in this series.
5 KOLs are featured in this series.
This series features 1 KOL.
1 KOL is featured in this series.
This series features 1 kol.
This series features 1 KOL.
This series features 1 KOL.
This series features 1 kol.
Related Content

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo